WO2005104722A2 - Crude extracts from andrographis paniculata - Google Patents

Crude extracts from andrographis paniculata Download PDF

Info

Publication number
WO2005104722A2
WO2005104722A2 PCT/US2005/014288 US2005014288W WO2005104722A2 WO 2005104722 A2 WO2005104722 A2 WO 2005104722A2 US 2005014288 W US2005014288 W US 2005014288W WO 2005104722 A2 WO2005104722 A2 WO 2005104722A2
Authority
WO
WIPO (PCT)
Prior art keywords
andrographolide
weight
deoxy
extract
neoandrographolide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/014288
Other languages
French (fr)
Other versions
WO2005104722A3 (en
Inventor
Xiaoqiang Yan
Tao Wang
Zhiming Ma
Weihan Zhang
Jifen Duan
Yu Cai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hutchmed Holdings Enterprises Ltd
Original Assignee
Hutchison Medipharma Enterprises Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Enterprises Ltd filed Critical Hutchison Medipharma Enterprises Ltd
Priority to CA2564637A priority Critical patent/CA2564637C/en
Priority to ES05742174.5T priority patent/ES2534594T3/en
Priority to JP2007510891A priority patent/JP5221128B2/en
Priority to KR1020157010077A priority patent/KR101536892B1/en
Priority to DK05742174T priority patent/DK1747008T3/en
Priority to KR1020137001151A priority patent/KR101531116B1/en
Priority to AU2005237550A priority patent/AU2005237550B2/en
Priority to KR1020067025043A priority patent/KR101534844B1/en
Priority to PL05742174T priority patent/PL1747008T3/en
Priority to EP05742174.5A priority patent/EP1747008B1/en
Publication of WO2005104722A2 publication Critical patent/WO2005104722A2/en
Publication of WO2005104722A3 publication Critical patent/WO2005104722A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/19—Acanthaceae (Acanthus family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Definitions

  • TNF- ⁇ Tumor Necrosis Factor alpha
  • TNF- ⁇ disorders related to expression of TNF- ⁇ include, but are not limited to, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, spondyloarthropathies, inflammatory bowel disease (including Crohn's disease and ulcerative colitis), chronic heart failure, systemic lupus erythematosus, scleroderma, sarcoidosis, polymyositis/dermatomyositis, psoriasis, multiple myeloma, myelodysplastic syndrome, acute myelogenous leukemia, Parkinson's disease, AIDS dementia complex, Alzheimer's disease, depression, sepsis, pyoderma gangrenosum, hematosepsis, septic shock, Behcet's syndrome, graft- versus-host disease, uveitis, Wegener's granulomatosis, Sjogren's syndrome, chronic obstructive pulmonary
  • Interleukin-1 beta IL-l ⁇
  • IL-l ⁇ Interleukin-1 beta
  • the extract obtained from the aerial part of Andrographis paniculata, contains andrographolide, 14-deoxy-andrographolide, 14-deoxy- 11,12-dehydrogen- andrographolide, and neoandrographolide.
  • the extract contains 2- 20% by weight andrographolide, 1-6% by weight 14-deoxy-andrographolide, 1- 12% by weight 14-deoxy- 11,12-dehydrogen-andrographolide, and 1 -5 % by weight neoandrographolide.
  • the extract contains 3-8% by weight andrographolide, 3-5% by weight 14-deoxy-andrographolide, 7-9% by weight 14-deoxy- 11,12-dehydrogen-andrographolide, and 2-4% by weight neoandrographolide. It is particularly preferred that the extract contain 4.2% by weight andrographolide, 4.4% by weight 14-deoxy-andrographolide, 8% by weight 14-deoxy- 11,12-dehydrogen-andrographolide, and 2.1% by weight neoandrographolide.
  • One aspect of this invention relates to a method of inhibiting expression of TNFc. or IL-l ⁇ in a subject. The method includes administering to the subject an effective amount of the above-described extract.
  • Another aspect of this invention relates to a method of treating a disorder related to TNFa or LL-l ⁇ , i.e., inflammatory bowel disease (including Crohn's disease and ulcerative colitis), chronic heart failure, diabetes mellitus, systemic lupus erythematosus, polymyositis/dermatomyositis, psoriasis, acute myelogenous leukemia, ALDS dementia complex, hematosepsis, septic shock, graft- versus-host disease, uveitis, asthma, acute pancreatitis, or periodontal disease.
  • the method includes administering to a subject in need of the treatment an effective amount of the above-described extract.
  • compositions containing the extract of this invention described above for use in treating TNFc. related disorders and IL-1/3 related disorders as well as the use of such a composition for the manufacture of a medicament for treating these disorders are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from the description, and also from the claims.
  • This invention includes methods of inhibiting expression of TNFc. or IL- 1 ⁇ , treating a TNFc. related-disorder, and treating an IL- 1 -realted disorder by administering to a subject in need thereof an effective amount of the above- described extract.
  • an effective amount refers to the amount of the extract which is required to confer one of the above-described effects in the subject. Effective amounts may vary, as recognized by those skilled in the art, depending on route of administration, excipient usage, and the possibility of co- usage with other agents.
  • treating refers to administering the extract to a subject that has a TNFc.
  • an extract for use in this invention one can immerse the aerial part of Andrographis paniculata in one or more suitable solvents, e.g., ethanol, methanol, and acetone; separate the liquid from the solid residue; and concentrate the liquid.
  • suitable solvents e.g., ethanol, methanol, and acetone
  • compositions that is either the above-mentioned extract alone or a mixture of the extract and a pharmaceutically acceptable carrier.
  • parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
  • An oral composition can be any orally acceptable dosage form including, but not limited to, tablets, capsules, emulsions and aqueous suspensions, dispersions and solutions.
  • Commonly used carriers for tablets include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added to tablets.
  • useful diluents include lactose and dried corn starch.
  • aqueous suspensions or emulsions are administered orally, the active ingredient can be suspended or dissolved in an oily phase combined with emulsifying or suspending agents. If desired, certain sweetening, flavoring, or coloring agents can be added.
  • a sterile injectable composition e.g., aqueous or oleaginous suspension
  • suitable dispersing or wetting agents such as, for example, Tween 80
  • the sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • a non-toxic parenterally acceptable diluent or solvent for example, as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that can be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium (e.g., synthetic mono- or di-glycerides).
  • Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • oil solutions or suspensions can also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents.
  • An inhalation composition can be prepared according to techniques well known in the art of pharmaceutical formulation and can be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
  • a topical composition can be formulated in form of oil, cream, lotion, ointment and the like. Suitable carriers for the composition include vegetable or mineral oils, white petrolatum (white soft paraffin), branched chain fats or oils, animal fats and high molecular weight alcohols (greater than C12). The preferred carriers are those in which the active ingredient is soluble.
  • Emulsifiers, stabilizers, humectants and antioxidants may also be included as well as agents imparting color or fragrance, if desired.
  • transdermal penetration enhancers may be employed in these topical formulations. Examples of such enhancers can be found in U.S. Patents 3,989,816 and 4,444,762.
  • Creams are preferably formulated from a mixture of mineral oil, self-emulsifying beeswax and water in which mixture the active ingredient, dissolved in a small amount of an oil, such as almond oil, is admixed.
  • An example of such a cream is one which includes about 40 parts water, about 20 parts beeswax, about 40 parts mineral oil and about 1 part almond oil.
  • Ointments may be formulated by mixing a solution of the active ingredient in a vegetable oil, such as almond oil, with warm soft paraffin and allowing the mixture to cool.
  • An example of such an ointment is one which includes about 30% almond and about 70% white soft paraffin by weight.
  • a carrier in a pharmaceutical composition must be "acceptable” in the sense of being compatible with the active ingredient of the formulation (and preferably, capable of stabilizing it) and not deleterious to the subject to be treated.
  • solubilizing agents such as cyclodextrins (which form specific, more soluble complexes with one or more of active compounds of the extract), can be utilized as pharmaceutical excipients for delivery of the active compounds.
  • examples of other carriers include colloidal silicon dioxide, magnesium stearate, cellulose, sodium lauryl sulfate, and D&C Yellow # 10.
  • a suitable in vitro assay can be used to preliminarily evaluate the efficacy of the above-described extract in inhibiting expression of TNFc. or IL- I ⁇ expression.
  • the extract can further be examined for its efficacy in treating a TNFc. related disorder or an IL-1/3 related disorder by in vivo assays.
  • the extract can be administered to an animal (e.g., a mouse model) having a TNFc. or IL-1/3 related disorder and its therapeutic effects are then accessed. Based on the results, an appropriate dosage range and administration route can also be determined.
  • PBMC Peripheral blood monocytes
  • In vivo assays were conducted to evaluate the efficacy of the Andrographis paniculata extract in treating inflammatory bowel disease (IBD).
  • IBD inflammatory bowel disease
  • Balb/c male mice (18-24 g) were anaesthetized with 1 % pentobarbital sodium at 0.05 mg/10 g.
  • To induce LBD 1.5 mg of 2,4,6-trinitrobenzenesulfonic acid (TNBS; Sigma) in 50% ethanol was administered slowly to each mouse (except blank control mice) via a catheter. Blank control mice only received 0.1 ml of 50% ethanol.
  • the mice were treated with the extract of Andrographis paniculata 24 hours and 2 hours prior to the TNBS administration and daily for 5 days after the administration.
  • TNBS 2,4,6-trinitrobenzenesulfonic acid
  • the body weight of each mouse was monitored every day before and after the TNBS administration.
  • the mice were sacrificed 24 hours after the last administration of the extract. Colons were removed and weighed. Furthermore, the colon weight to body weight ratio was calculated and adhesion between colon and other organs was also monitored. Samples of colon tissues located precisely 2 cm above the anal canal were obtained, fixed in 10% buffered phosphate, embedded in paraffin, sectioned, and stained with hematoxylin/eosin.
  • the degree of inflammation on microscopic cross sections was graded from 0 to 4 (0: no signs of inflammation; 1: a very low level of inflammation; 2: a low level of leukocyte infiltration; 3: a high level of leukocyte infiltration, a high vascular density, and a thickened colon wall; and 4: transmural infiltrations, loss of goblet cells, a high vascular density, and a thickened colon wall).
  • the results show that when mice were treated with 150 mg/kg TNBS alone, they had severe illness characterized by diarrhea, profound and sustained weight losses, a significant increase of the colon weight to body weight ratio, and a mortality rate of 50%. Macroscopic examination indicates that the colon of each of mice had transmural inflammation in all layers of the bowel wall.
  • mice were treated with the extract of Andrographis paniculata (500 mg/kg/day) prior to the induction of LBD, they had a reduced overall mortality rate, less severe wasting syndrome, a lower colon weight to body weight ratio, and a lower IBD score.
  • the bowel wall was sleek and was not adhesive with surrounding tissues.
  • male Wistar rats were used to evaluate the efficacy of the Andrographis paniculata extract in treating IBD following a procedure similar to that described above. To induce IBD, the rats were administered with 2,4-dinitrobenzenesulfonic acid, instead of TNBS. Similar results were obtained. Specifically, rats treated with the Andrographis paniculata extract had a reduced overall mortality rate, less severe wasting syndrome, a lower colon weight to body weight ratio, and a lower IBD score, compared with those not treated with the extract.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

This invention relates to a method of inhibiting TNFα or IL-1β expression with an extract of Andrographis paniculata. The extract contains andrographolide, 14-deoxy-andrographolide, 14-deoxy-I 1, 12-dehydrogen­andrographolide, and neoandrographolide.

Description

CRUDE EXTRACTS FROM ANDROGRAPHIS PANICULATA
CROSS REFERENCE TO RELATED APPLICATIONS Pursuant to 35 USC § 119(e), this application claims priority to U.S. Provisional Application Serial No. 60/566,477, filed April 28, 2004, the contents of which are incorporated herein by reference.
BACKGROUND Tumor Necrosis Factor alpha (TNF-α), a mononuclear cytokine, is predominantly produced by monocytes and macrophages. It possesses various biological activities: (1) killing cancer cells or inhibiting growth of cancer cells, (2) enhancing phagocytosis of neutrophilic granulocyte, (3) killing infectious pathogens, and (4) increasing expression of adhesion molecules on vascular endothelial cells during inflammatory responses. Disorders related to expression of TNF-α include, but are not limited to, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, spondyloarthropathies, inflammatory bowel disease (including Crohn's disease and ulcerative colitis), chronic heart failure, systemic lupus erythematosus, scleroderma, sarcoidosis, polymyositis/dermatomyositis, psoriasis, multiple myeloma, myelodysplastic syndrome, acute myelogenous leukemia, Parkinson's disease, AIDS dementia complex, Alzheimer's disease, depression, sepsis, pyoderma gangrenosum, hematosepsis, septic shock, Behcet's syndrome, graft- versus-host disease, uveitis, Wegener's granulomatosis, Sjogren's syndrome, chronic obstructive pulmonary disease, asthma, acute pancreatitis, periodontal disease, cachexia, central nervous system injury, cancer (e.g., lung carcinomas, esophagus carcinoma, gastric adenocarcinoma, and prostate carcinoma), viral respiratory disease, and obesity. See, e.g., Ogata H. et al Curr Pharm Des. 2003; 9(14): 1107-13; Moller D.R. et al J Intern Med. 2003; 253(1): 31-40; Taylor PC. et al Curr Pharm Des. 2003; 9(14): 1095-106; Wilkinson N. et al Arch Dis Child. 2003; 88(3): 186-91; Nishimura F. et al J Periodontol. 2003; 74(1): 97- 102; Weinberg J.M. et al Cutis. 2003; 71(1): 41-5; Burnham E. et al Crit Care Med. 2001 ; 29(3): 690-1 ; Sack M. et al Pharmacol Then 2002; 94(1-2): 123-35; Barnes P et alAnnu Rev Pharmacol Toxicol. 2002; 42:81-98; Mageed R.A. et al Lupus 2002; 11(12): 850-5; Tsimberidou A.M. et al Expert Rev Anticancer Then 2002; 2(3): 277-86; Muller T. et al Curr Opin Investig Drugs. 2002; 3(12): 1763-7; Calandra T. et al Curr Clin Top Infect Dis. 2002; 22:1-23; Girolomoni G et al Curr Opin Investig Drugs. 2002; 3(11): 1590-5; Tutuncu Z. et al Clin Exp Rheumatol. 2002; 20(6 Suppl 28): S146-51; Braun J. et al Best Pract Res Clin Rheumatol. 2002; 16(4): 631-51; Barnes P.J. et al Novartis Found Symp. 2001; 234:255-67; discussion 267-72; Brady M. et al Baillieres Best Pract Res Clin Gastroenterol. 1999; 13(2): 265-89; Goldring M.B. et al Expert Opin Biol Ther. 2001; 1(5): 817-29; Mariette X. RevPrat. 2003; 53(5): 507-11; SharmaR. et al IntJCardiol. 2002; 85(1): 161-71; Wang C.X. et al Prog Neurobiol. 2002; 67(2): 161-72; Nan Reeth K. et al Vet Immunol Immunopathol. 2002; 87(3-4): 161-8; Leonard B.E. et al lnt J Dev Neurosci. 2001; 19(3): 305-12; and Hays S.J. et al CurrPhαrm Des. 1998; 4(4): 335-48. Interleukin-1 beta (IL-lβ), a cytokine secreted by cells such as monocytes, macrophages and dendritic cells, mediates a wide range of immune and inflammatory responses. One can modulate IL-1/3 production to treat a variety of disorders, such as rheumatoid arthritis, hematosepsis, periodontal disease, chronic heart failure, polymyositis/dermatomyositis, acute pancreatitis, chronic obstructive pulmonary disease, Alzheimer's disease, osteo arthritis, bacterial infections, multiple myeloma, myelodysplastic syndrome, uveitis. central nervous system injury, viral respiratory disease, asthma, depression, and scleroderma. See, e.g., Taylor P.C. et al CurrPhαrm Des. 2003; 9(14): 1095- 106; Dellinger R.P. et al Clin Infect Dis. 2003; 36(10): 1259-65; Takashiba S. et alJ Peήodontol. 2003; 74(1): 103-10; Diwan A. et al Curr Mol Med. 2003; 3(2): 161-82; Lundberg I.E. et al Rheum Dis Clin North Am. 2002; 28(4): 799-822; Makhija R. et al J Hepatobiliary Pancreat Surg. 2002; 9(4): 401-10; Chung K.F. et al Eur Respir J Suppl. 2001; 34:50s-59s; Hallegua D.S. et al Ann Rheum Dis. 2002; 61(11): 960-7; Goldring M.B. et al Expert Opin Biol Ther. 2001; 1(5): 817-29; Mrak R.Ε. et al Neurobiol Aging. 2001; 22(6): 903-8; Brady M. et al Baillieres Best Pract Res Clin Gastroenterol. 1999; 13(2): 265-89; Nan der Meer J.W. et al Ann N YAcadSci. 1998; 856:243-51; RameshwarP. et al -4ctα
Haematol. 2003; 109(1): 1-10; de Kozak Y et al Int Rev Immunol. 2002; 21(2-3): 231-53; Wang C.X. et al Prog Neurobiol. 2002; 67(2): 161-72; Nan Reeth K. et al Vet Immunol Immunopathol. 2002; 87(3-4): 161-8; Stirling R.G. et al BrMed Bull. 2000; 56(4): 1037-53; Leonard B.E. et al bit JDev Neurosci. 2001; 19(3): 305-12; Allan S.M. et al Ann N YAcad Sci. 2000; 917:84-93; and Cafagna D. et al Minerva Med. 1998; 89(5): 153-61.
SUMMARY This invention is based on a surprising discovery that an extract of Andrographis paniculata inhibits expression of both TNFc. and IL-lβ. The extract, obtained from the aerial part of Andrographis paniculata, contains andrographolide, 14-deoxy-andrographolide, 14-deoxy- 11,12-dehydrogen- andrographolide, and neoandrographolide. Preferably, the extract contains 2- 20% by weight andrographolide, 1-6% by weight 14-deoxy-andrographolide, 1- 12% by weight 14-deoxy- 11,12-dehydrogen-andrographolide, and 1 -5 % by weight neoandrographolide. More preferably, the extract contains 3-8% by weight andrographolide, 3-5% by weight 14-deoxy-andrographolide, 7-9% by weight 14-deoxy- 11,12-dehydrogen-andrographolide, and 2-4% by weight neoandrographolide. It is particularly preferred that the extract contain 4.2% by weight andrographolide, 4.4% by weight 14-deoxy-andrographolide, 8% by weight 14-deoxy- 11,12-dehydrogen-andrographolide, and 2.1% by weight neoandrographolide. One aspect of this invention relates to a method of inhibiting expression of TNFc. or IL-lβ in a subject. The method includes administering to the subject an effective amount of the above-described extract. Another aspect of this invention relates to a method of treating a disorder related to TNFa or LL-lβ, i.e., inflammatory bowel disease (including Crohn's disease and ulcerative colitis), chronic heart failure, diabetes mellitus, systemic lupus erythematosus, polymyositis/dermatomyositis, psoriasis, acute myelogenous leukemia, ALDS dementia complex, hematosepsis, septic shock, graft- versus-host disease, uveitis, asthma, acute pancreatitis, or periodontal disease. The method includes administering to a subject in need of the treatment an effective amount of the above-described extract. Also within the scope of this invention is a composition containing the extract of this invention described above for use in treating TNFc. related disorders and IL-1/3 related disorders as well as the use of such a composition for the manufacture of a medicament for treating these disorders. Details of several embodiments of the invention are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from the description, and also from the claims.
DETAILED DESCRIPTION This invention includes methods of inhibiting expression of TNFc. or IL- 1 β, treating a TNFc. related-disorder, and treating an IL- 1 -realted disorder by administering to a subject in need thereof an effective amount of the above- described extract. The term "an effective amount" refers to the amount of the extract which is required to confer one of the above-described effects in the subject. Effective amounts may vary, as recognized by those skilled in the art, depending on route of administration, excipient usage, and the possibility of co- usage with other agents. The term "treating" refers to administering the extract to a subject that has a TNFc. related disorder or an IL-lβ related disorder, or has a symptom of the disorder, or has a predisposition toward the disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the disorder, the symptoms of the disorder, or the predisposition toward the disorder. To prepare an extract for use in this invention, one can immerse the aerial part of Andrographis paniculata in one or more suitable solvents, e.g., ethanol, methanol, and acetone; separate the liquid from the solid residue; and concentrate the liquid. The extract thus obtained may be further processed. For example, one can remove impurities or modify the ratio of the components by chromatography. To practice one of the above-described methods, one administers to a subject in need thereof orally, rectally, parenterally, by inhalation spray, or via an implanted reservoir a composition that is either the above-mentioned extract alone or a mixture of the extract and a pharmaceutically acceptable carrier. The term "parenteral" as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques. An oral composition can be any orally acceptable dosage form including, but not limited to, tablets, capsules, emulsions and aqueous suspensions, dispersions and solutions. Commonly used carriers for tablets include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added to tablets. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions or emulsions are administered orally, the active ingredient can be suspended or dissolved in an oily phase combined with emulsifying or suspending agents. If desired, certain sweetening, flavoring, or coloring agents can be added. A sterile injectable composition (e.g., aqueous or oleaginous suspension) can be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents. The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium (e.g., synthetic mono- or di-glycerides). Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions can also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents. An inhalation composition can be prepared according to techniques well known in the art of pharmaceutical formulation and can be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art. A topical composition can be formulated in form of oil, cream, lotion, ointment and the like. Suitable carriers for the composition include vegetable or mineral oils, white petrolatum (white soft paraffin), branched chain fats or oils, animal fats and high molecular weight alcohols (greater than C12). The preferred carriers are those in which the active ingredient is soluble.
Emulsifiers, stabilizers, humectants and antioxidants may also be included as well as agents imparting color or fragrance, if desired. Additionally, transdermal penetration enhancers may be employed in these topical formulations. Examples of such enhancers can be found in U.S. Patents 3,989,816 and 4,444,762.
Creams are preferably formulated from a mixture of mineral oil, self-emulsifying beeswax and water in which mixture the active ingredient, dissolved in a small amount of an oil, such as almond oil, is admixed. An example of such a cream is one which includes about 40 parts water, about 20 parts beeswax, about 40 parts mineral oil and about 1 part almond oil. Ointments may be formulated by mixing a solution of the active ingredient in a vegetable oil, such as almond oil, with warm soft paraffin and allowing the mixture to cool. An example of such an ointment is one which includes about 30% almond and about 70% white soft paraffin by weight. A carrier in a pharmaceutical composition must be "acceptable" in the sense of being compatible with the active ingredient of the formulation (and preferably, capable of stabilizing it) and not deleterious to the subject to be treated. For example, solubilizing agents, such as cyclodextrins (which form specific, more soluble complexes with one or more of active compounds of the extract), can be utilized as pharmaceutical excipients for delivery of the active compounds. Examples of other carriers include colloidal silicon dioxide, magnesium stearate, cellulose, sodium lauryl sulfate, and D&C Yellow # 10. A suitable in vitro assay can be used to preliminarily evaluate the efficacy of the above-described extract in inhibiting expression of TNFc. or IL- Iβ expression. The extract can further be examined for its efficacy in treating a TNFc. related disorder or an IL-1/3 related disorder by in vivo assays. For example, the extract can be administered to an animal (e.g., a mouse model) having a TNFc. or IL-1/3 related disorder and its therapeutic effects are then accessed. Based on the results, an appropriate dosage range and administration route can also be determined. Without further elaboration, it is believed that the above description has adequately enabled the present invention. The following specific examples are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. All of the publications, including patents, cited herein are hereby incorporated by reference in their entirety.
Preparation of an extract of Andi-oεraphis paniculata Dried powder of the aerial part of Andrographis paniculata (1 kg) was suspended in 85% ethanol. The suspension was refluxed for two hours and filtered. The residue was extracted with 85% ethanol again. The combined ethanol solutions were cooled and concentrated to afford 105 g of the desired extract. HPLC analysis shows that the extract contained 4.0% andrographolide.
In vitro assay An in vitro assay was conducted to evaluate the efficacy of the Andrographis paniculata extract in inhibiting expression of TNFc- and IL-lβ expression. Peripheral blood monocytes (PBMC) cells were isolated from fresh blood using the Ficoll-Paque Plus (Amersham Bioscience) according to the protocol recommended by the manufacturer. The cells were suspended in RPMI 1640 media containing 10% FBS at a concentration of lxlO5 cells/ml and seeded in a 96-well plate (lxlO4 cells total in each well). Each reaction was carried out in three wells. 10 μl of the Andrographis paniculata extract in DMSO was added into each well (final concentrations: 0.1, 0.3, 1, 3, 10, and 30 μg/ml). Wells containing dexamethason (CalBiochem.) at the final concentration of 10 μM were used as positive control. Wells containing 10 μl of the media were used as negative control. The plate was incubated at 37°C under 5% CO for 15 minutes. After 10 μl aliquots of 100 μg/ml lipopolysaccharide were added to all wells except for the negative control, the plate was incubated at 37°C under 5% CO2 overnight. The plate was spun at 1000 rpm for 15 minutes and the supernatants were collected. Concentrations of TNFc. and IL-1/3 were measured using the TNFc. ELISA (Enzyme Linked lmmunosorbent Assay) Kit and ILl-β ELISA Kit (Jingmei Bioengineer Technology). The inhibition ratio was calculated as follows: '-'extract " ^Control Inhibition Ratio ( % ) = ( 1 ) xlOO CLPS " Ccontrol where Cextract is the concentration of TNFc. or IL-lβ in PBMC cells treated with the extract and LPS, C PS is the concentration of TNFc. or IL-1/3 in PBMC cells treated with LPS and dexamethason, and Ccontrol is the concentration of TNFc. or IL-1/3 in PBMC cells without being treated with LPS or the extract. The results show that the extract significantly inhibited expression of both TNFc. and IL-lβ.
In vivo assays In vivo assays were conducted to evaluate the efficacy of the Andrographis paniculata extract in treating inflammatory bowel disease (IBD). Balb/c male mice (18-24 g) were anaesthetized with 1 % pentobarbital sodium at 0.05 mg/10 g. To induce LBD, 1.5 mg of 2,4,6-trinitrobenzenesulfonic acid (TNBS; Sigma) in 50% ethanol was administered slowly to each mouse (except blank control mice) via a catheter. Blank control mice only received 0.1 ml of 50% ethanol. The mice were treated with the extract of Andrographis paniculata 24 hours and 2 hours prior to the TNBS administration and daily for 5 days after the administration. The body weight of each mouse was monitored every day before and after the TNBS administration. The mice were sacrificed 24 hours after the last administration of the extract. Colons were removed and weighed. Furthermore, the colon weight to body weight ratio was calculated and adhesion between colon and other organs was also monitored. Samples of colon tissues located precisely 2 cm above the anal canal were obtained, fixed in 10% buffered phosphate, embedded in paraffin, sectioned, and stained with hematoxylin/eosin. The degree of inflammation on microscopic cross sections was graded from 0 to 4 (0: no signs of inflammation; 1: a very low level of inflammation; 2: a low level of leukocyte infiltration; 3: a high level of leukocyte infiltration, a high vascular density, and a thickened colon wall; and 4: transmural infiltrations, loss of goblet cells, a high vascular density, and a thickened colon wall). The results show that when mice were treated with 150 mg/kg TNBS alone, they had severe illness characterized by diarrhea, profound and sustained weight losses, a significant increase of the colon weight to body weight ratio, and a mortality rate of 50%. Macroscopic examination indicates that the colon of each of mice had transmural inflammation in all layers of the bowel wall. In contrast, when mice were treated with the extract of Andrographis paniculata (500 mg/kg/day) prior to the induction of LBD, they had a reduced overall mortality rate, less severe wasting syndrome, a lower colon weight to body weight ratio, and a lower IBD score. The bowel wall was sleek and was not adhesive with surrounding tissues. In a separate assay, male Wistar rats were used to evaluate the efficacy of the Andrographis paniculata extract in treating IBD following a procedure similar to that described above. To induce IBD, the rats were administered with 2,4-dinitrobenzenesulfonic acid, instead of TNBS. Similar results were obtained. Specifically, rats treated with the Andrographis paniculata extract had a reduced overall mortality rate, less severe wasting syndrome, a lower colon weight to body weight ratio, and a lower IBD score, compared with those not treated with the extract.
OTHER EMBODIMENTS A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are also within the scope of the following claims.

Claims

WHAT IS CLAIMED IS:
1. A method of inhibiting expression of TNFc- in a subj ect in need thereof, comprising administering to the subject an effective amount of an extract of Andrographis paniculata.
2. The method of claim 1, wherein the extract contains andrographolide, 14-deoxy-andrographolide, 14-deoxy- 11, 12-dehydrogenandrographolide, and neoandrographolide.
3. The method of claim 2, wherein the extract contains 2-20% by weight andrographolide, 1-6% by weight 14-deoxy-andrographolide, 1-12% by weight 14-deoxy-l l, 12-dehydrogen-andrographolide, and 1-5% by weight neoandrographolide.
4. The method of claim 3, wherein the extract contains 3-8% by weight andrographolide, 3-5% by weight 14-deoxy-andrographolide, 7-9% by weight 14-deoxy- 11,12-dehydrogen-andrographolide, and 2-4% by weight neoandrographolide.
5. The method of claim 4, wherein the extract contains 4.2% by weight andrographolide, 4.4% by weight 14-deoxy-andrographolide, 8% by weight 14-deoxy-l 1,12-dehydrogen-andrographolide, and 2.1% by weight neoandrographolide.
6. A method of inhibiting expression of IL- 1 β in a subj ect in need thereof, comprising administering to the subject an effective amount of an extract of Andrographis paniculata.
7. The method of claim 6, wherein the extract contains andrographolide, 14-deoxy-andrographolide, 14-deoxy-l 1,12-dehydrogen- andrographolide, and neoandrographolide.
8. The method of claim 7, wherein the extract contains 2-20% by weight andrographolide, 1-6% by weight 14-deoxy-andrographolide, 1-12% by weight 14-deoxy-l 1, 12-dehydrogen-andrographolide, and 1-5% by weight neoandrographolide.
9. The method of claim 8, wherein the extract contains 3-8% by weight andrographolide, 3-5% by weight 14-deoxy-andrographolide, 7-9% by weight 14-deoxy-l 1, 12-dehydrogen-andrographolide, and 2-4% by weight neoandrographolide.
10. The method of claim 9, wherein the extract contains 4.2% by weight andrographolide, 4.4% by weight 14-deoxy-andrographolide, 8% by weight 14-deoxy-l 1,12-dehydrogen-andrographolide, and 2.1% by weight neoandrographolide.
11. A method of treating an inflammatory bowel disease in a subject in need thereof, comprising administering to the subject an effective amount of an extract of Andrographis paniculata.
12. The method of claim 11 , wherein the extract contains andrographolide, 14-deoxy-andrographolide, 14-deoxy-l 1,12-dehydrogen- andrographolide, and neoandrographolide.
13. The method of claim 12, wherein the extract contains 2-20% by weight andrographolide, 1-6% by weight 14-deoxy-andrographolide, 1-12% by weight 14-deoxy- 11, 12-dehydrogen-andrographolide, and 1 -5 % by weight neoandrographolide.
14. The method of claim 13, wherein the extract contains 3-8% by weight andrographolide, 3-5% by weight 14-deoxy-andrographolide, 7-9% by weight 14-deoxy- 11 , 12-dehydrogen-andrographolide, and 2-4% by weight neoandrographolide.
15. The method of claim 14, wherein the extract contains 4.2% by weight andrographolide, 4.4% by weight 14-deoxy-andrographolide, 8% by weight 14-deoxy-l 1,12-dehydrogen-andrographolide, and 2.1% by weight neoandrographolide.
16. The method of claim 11 , wherein the inflammatory bowel disease is Crohn's disease.
17. The method of claim 16, wherein the extract contains andrographolide, 14-deoxy-andrographolide, 14-deoxy-l 1, 12-dehydrogenandrographolide, and neoandrographolide.
18. The method of claim 17, wherein the extract contains 2-20% by weight andrographolide, 1-6% by weight 14-deoxy-andrographolide, 1-12% by weight 14-deoxy-l 1, 12-dehydrogen-andrographolide, and 1-5% by weight neoandrographolide
19. The method of claim 11 , wherein the inflammatory bowel disease is ulcerative colitis.
20. The method of claim 19, wherein the extract contains andrographolide, 14-deoxy-andrographolide, 14-deoxy-l 1,12-dehydrogen- andrographolide, and neoandrographolide.
21. The method of claim 20, wherein the extract contains 2-20% by weight andrographolide, 1-6% by weight 14-deoxy-andrographolide, 1-12% by weight 14-deoxy-l 1, 12-dehydrogen-andrographolide, and 1-5% by weight neoandrographolide.
PCT/US2005/014288 2004-04-28 2005-04-26 Crude extracts from andrographis paniculata Ceased WO2005104722A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA2564637A CA2564637C (en) 2004-04-28 2005-04-26 Crude extracts from andrographis paniculata
ES05742174.5T ES2534594T3 (en) 2004-04-28 2005-04-26 Raw extracts of Andrographis paniculata
JP2007510891A JP5221128B2 (en) 2004-04-28 2005-04-26 Crude extract derived from Andrographis paniculata
KR1020157010077A KR101536892B1 (en) 2004-04-28 2005-04-26 Crude extracts from andrographis paniculata
DK05742174T DK1747008T3 (en) 2004-04-28 2005-04-26 Crude extract FROM Andrographis paniculata
KR1020137001151A KR101531116B1 (en) 2004-04-28 2005-04-26 Crude extracts from andrographis paniculata
AU2005237550A AU2005237550B2 (en) 2004-04-28 2005-04-26 Crude extracts from andrographis paniculata
KR1020067025043A KR101534844B1 (en) 2004-04-28 2005-04-26 Crude extract from Tenshin
PL05742174T PL1747008T3 (en) 2004-04-28 2005-04-26 Crude extracts from andrographis paniculata
EP05742174.5A EP1747008B1 (en) 2004-04-28 2005-04-26 Crude extracts from andrographis paniculata

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56647704P 2004-04-28 2004-04-28
US60/566,477 2004-04-28

Publications (2)

Publication Number Publication Date
WO2005104722A2 true WO2005104722A2 (en) 2005-11-10
WO2005104722A3 WO2005104722A3 (en) 2006-03-02

Family

ID=35242143

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014288 Ceased WO2005104722A2 (en) 2004-04-28 2005-04-26 Crude extracts from andrographis paniculata

Country Status (14)

Country Link
US (3) US7341748B2 (en)
EP (1) EP1747008B1 (en)
JP (1) JP5221128B2 (en)
KR (3) KR101531116B1 (en)
AU (1) AU2005237550B2 (en)
CA (1) CA2564637C (en)
DK (1) DK1747008T3 (en)
ES (1) ES2534594T3 (en)
HU (1) HUE025117T2 (en)
PL (1) PL1747008T3 (en)
PT (1) PT1747008E (en)
RU (1) RU2383353C2 (en)
TW (1) TWI373340B (en)
WO (1) WO2005104722A2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007176934A (en) * 2005-11-30 2007-07-12 Kose Corp Platelet-activating factor acetylhydrolase function regulator
JP2009544687A (en) * 2006-07-28 2009-12-17 インデナ エッセ ピ ア Methods for treating and preventing mucositis
WO2010110748A1 (en) * 2009-03-24 2010-09-30 National University Of Singapore Use of andrographolide compounds for treating inflammation and airway disorders
JP2011502995A (en) * 2007-11-02 2011-01-27 ハッチソン メディファーマ エンタープライジズ リミテッド Andrographis Paniculata Extract
USRE42718E1 (en) 2004-04-28 2011-09-20 Hutchison Medipharma Enterprises Limited Crude extracts from andrographis paniculata
CN102702147A (en) * 2012-06-18 2012-10-03 辽宁利锋科技开发有限公司 Andrographolide analogue and application of andrographolide analogue to treatment
CN103145661A (en) * 2013-03-25 2013-06-12 成都天台山制药有限公司 New crystal form of andrographolide
WO2017204619A1 (en) * 2016-05-23 2017-11-30 Universiti Putra Malaysia (Upm) Extract of andrographis paniculata for cognitive enhancement
WO2018081959A1 (en) * 2016-11-02 2018-05-11 Nutrition Science Partners Limited Extracts of andrographis paniculata, methods for preparation and use thereof
WO2022058422A1 (en) * 2020-09-17 2022-03-24 Dsm Ip Assets B.V. Use of andrographis paniculata extract to protect against air pollution related diseases

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2559614A1 (en) * 2004-03-11 2005-09-22 Hutchison Medipharma Ltd. Andrographolide and analogues as inhibitors of tnf.alpha. and il-1.beta.expression
US20070202164A1 (en) * 2006-02-28 2007-08-30 Hutchison Medipharma Enterprises Limited Andrographis Extract Formulations
MD480Z (en) * 2011-07-07 2012-09-30 Elvira Andon Method for treating acute ulcerative nonspecific colitis
CN103145660B (en) * 2013-03-25 2014-09-17 成都天台山制药有限公司 Andrographolide and preparation method thereof
CN103223028A (en) * 2013-03-27 2013-07-31 张宗升 Extract product of traditional Chinese medicine
CN103766901A (en) * 2014-01-08 2014-05-07 浙江大学 Application of andrographolide C to preparation of weight-losing food or medicine
JP6386761B2 (en) * 2014-03-19 2018-09-05 花王株式会社 Involucrin expression inhibitor
CN107349253A (en) * 2017-06-23 2017-11-17 苏州凌科特新材料有限公司 Non-stimulated Medical antiseptic solution and preparation method thereof
WO2024092327A1 (en) * 2022-10-31 2024-05-10 Mey, Angelica Machado Composition for obtaining a natural bioactive compound for cancer treatment
KR102713383B1 (en) * 2023-09-04 2024-10-04 김현주 Composition for enhancing the immunity of animals other than humans

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1042077A (en) 1989-07-29 1990-05-16 郭如明 Alkali water process for plumula Nelumbinis
JP2001058969A (en) 1999-08-20 2001-03-06 Nettairin Saisei Gijutsu Kenkyu Kumiai Nitric oxide production inhibitor
CN1488376A (en) 2003-05-09 2004-04-14 江西诚志信丰药业有限责任公司 Medicinal cap sule for treating enteric disease and nusosinusitis and preparing method thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017605A1 (en) * 1994-12-06 1996-06-13 Paracelsian, Inc. Use of andrographolide compounds to treat or prevent pathogenicity of diseases
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
DK1074268T3 (en) * 1998-03-17 2008-04-28 Chugai Pharmaceutical Co Ltd IL-6 receptor antagonist antibody-containing preventative or therapeutic agents for inflammatory bowel diseases
JP2000034233A (en) * 1998-07-15 2000-02-02 Sumitomo Forestry Co Ltd Nitric oxide production inhibitor
WO2002009699A2 (en) 2000-07-28 2002-02-07 Immupharm Aps Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract
US6629835B2 (en) 2000-08-01 2003-10-07 Metaproteomics, Llc Combinations of diterpene triepoxide lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2
US6358526B1 (en) 2000-08-16 2002-03-19 Rexall Sundown Method of making tablets and tablet compositions produced therefrom
US7270835B2 (en) 2001-06-20 2007-09-18 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US20030101076A1 (en) 2001-10-02 2003-05-29 Zaleski John R. System for supporting clinical decision making through the modeling of acquired patient medical information
US6753017B2 (en) 2001-11-07 2004-06-22 Jrs Pharma Lp Process for preparing dry extracts
JP2003171301A (en) 2001-11-09 2003-06-20 Mahidol Univ Calmeggel as an adjunct in the treatment of periodontitis
JP4669920B2 (en) 2002-08-21 2011-04-13 沖縄県 Functional material that suppresses blood glucose rise and blood pressure rise
CN1626076B (en) 2003-12-11 2010-10-06 天津天士力制药股份有限公司 A kind of andrographolide dropping pill and preparation method thereof
KR101065608B1 (en) 2003-12-29 2011-09-19 주식회사 엘지생활건강 Itching inhibiting or alleviating composition comprising cheonsimyeon extract containing andrographolide and andrographolide as an active ingredient
CA2559614A1 (en) 2004-03-11 2005-09-22 Hutchison Medipharma Ltd. Andrographolide and analogues as inhibitors of tnf.alpha. and il-1.beta.expression
WO2005104722A2 (en) 2004-04-28 2005-11-10 Hutchison Medipharma Enterprises Limited Crude extracts from andrographis paniculata
US20070218114A1 (en) 2004-06-12 2007-09-20 Passionfor Life Healthcare Limited Soluble Strip for Oral or Topical Administration
CN1628764A (en) 2004-08-19 2005-06-22 贵阳云岩西创药物科技开发有限公司 Creat formulation and its preparation process
US20070202164A1 (en) 2006-02-28 2007-08-30 Hutchison Medipharma Enterprises Limited Andrographis Extract Formulations
US20090117209A1 (en) 2007-11-02 2009-05-07 Hutchison Medipharma Enterprises Limited Andrographis paniculata extract

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1042077A (en) 1989-07-29 1990-05-16 郭如明 Alkali water process for plumula Nelumbinis
JP2001058969A (en) 1999-08-20 2001-03-06 Nettairin Saisei Gijutsu Kenkyu Kumiai Nitric oxide production inhibitor
CN1488376A (en) 2003-05-09 2004-04-14 江西诚志信丰药业有限责任公司 Medicinal cap sule for treating enteric disease and nusosinusitis and preparing method thereof

Non-Patent Citations (58)

* Cited by examiner, † Cited by third party
Title
ALLAN S.M. ET AL., ANN N YACAD SCI., vol. 917, 2000, pages 84 - 93
BALMAIN; CONNOLLY, JOURNAL OF THE CHEMICAL SOCIETY, PERKINS TRANSACTIONL, vol. 12, 1972, pages 1247 - 1251
BAMES P. J. ET AL., ANNU REV PHARMACOL TOXICOL., vol. 42, 2002, pages 81 - 98
BAMES P. J. ET AL., NOVARTIS FOUND SYMP, vol. 234, 2001, pages 255 - 67
BHAN ET AL., SCIENTIA HORTICULTURAE, vol. 107, 2005, pages 386 - 391
BRADY M. ET AL., BAILLIERES BEST PRACT RES CLIN GASTROENTEROL., vol. 13, no. 2, 1999
BRADY M. ET AL., BAILLIERES BEST PRACT RES CLIN GASTROENTEROL., vol. 13, no. 2, 1999, pages 265 - 89
BRAUN J. ET AL., BEST PRACT RES CLIN RHEUMATOL., vol. 16, no. 4, 2002, pages 631 - 51
BURNHAM E. ET AL., CRIT CARE MED., vol. 29, no. 3, 2001, pages 690 - 1
CAFAGNA D. ET AL., MINERVA MED., vol. 89, no. 5, 1998, pages 153 - 61
CALANDRA T. ET AL., CURR CLIN TOP INFECT DIS., vol. 22, 2002, pages 1 - 23
CHUNG K.F. ET AL., EUR RESPIR J, vol. 34, 2001, pages 50S - 59S
DE KOZAK Y ET AL., INT REV IMMUNOL., vol. 21, no. 2-3, 2002, pages 231 - 53
DELLINGER R.P. ET AL., CLIN INFECT DIS., vol. 36, no. 10, 2003, pages 1259 - 65
DIWAN A. ET AL., CURR MOL MED., vol. 3, no. 2, 2003, pages 161 - 82
GIROLOMONI G ET AL., CURR OPIN INVESTIG DRUGS., vol. 3, no. 11, 2002
GOLDRING M. B. ET AL., EXPERT OPIN BIOL THER, vol. 1, no. 5, 2001, pages 817 - 29
GOLDRING M. B. ET AL., EXPERT OPIN BIOL THER., vol. 1, no. 5, 2001, pages 817 - 29
GUPTA ET AL., INTERNATIONAL JOURNAL OF PHARMACOGNOSY, vol. 31, no. 3, 1993, pages 198 - 204
HABTEMARIAM: "Phytotherapy research", 1998, JOHN WILY & SONS, pages: 37 - 40
HALLEGUA D. S. ET AL., ANN RHEUM DIS., vol. 61, no. 11, 2002, pages 960 - 7
HANCKE ET AL., PHYTOTHERAPY RESEARCH, vol. 9, 1994, pages 559 - 562
HAYS S.J. ET AL., CURR PHARM DES., vol. 4, no. 4, 1998, pages 335 - 48
KAKRANI; SALUJA, JOURNAL OF NATURAL REMEDIES, vol. 2/1, 2001, pages 71 - 75
LEONARD B. E. ET AL., INT JDEV NEUROSCI., vol. 19, no. 3, 2001, pages 305 - 12
LEONARD B.E. ET AL., INT J DEV NEUROSCI., vol. 19, no. 3, 2001, pages 305 - 12
LUNDBERG I.E. ET AL., RHEUM DIS CLIN NORTH AM., vol. 28, no. 4, 2002, pages 799 - 822
MAGEED R.A. ET AL., LUPUS, vol. 11, no. 12, 2002, pages 850 - 5
MAKHIJA R. ET AL., J HEPATOBILIARY PANCREAT SURG., vol. 9, no. 4, 2002, pages 401 - 10
MARIETTE X., REV PRAT., vol. 53, no. 5, 2003, pages 507 - 11
MELCHIOR ET AL., PHYTOMEDICINE, vol. 7, no. 5, 2000, pages 341 - 350
MOLLER D. R ET AL., J INTERN MED., vol. 253, no. 1, 2003, pages 31 - 40
MRAK R. E. ET AL., NEUROBIOL AGING., vol. 22, no. 6, 2001
MULLER T. ET AL., CURR OPIN INVESTIG DRUGS., vol. 3, no. 12, 2002, pages 1763 - 7
NISHIMURA F. ET AL., J PERIODONTOL., vol. 74, no. 1, 2003, pages 97 - 102
OGATA H. ET AL., CURR PHARM DES., vol. 9, no. 14, 2003, pages 1107 - 13
PANOSSIAN ET AL., PHYTOMEDICINE, vol. 6, no. 3, 1999, pages 157 - 162
PURI ET AL., JOURNAL OF NATURAL PRODUCTS, vol. 56, no. 7, 1993, pages 995 - 999
RAMESHWAR P. ET AL., ACTA HAEMATOL., vol. 109, no. 1, 2003, pages 1 - 10
SACK M. ET AL., PHARMACOL THER., vol. 94, no. 1-2, 2002, pages 123 - 35
SAXENA ET AL., PHYTOCHEMICAL ANALYSIS, vol. 11, 1998, pages 34 - 36
See also references of EP1747008A4
SHARMA R. ET AL., INT J CARDIOL., vol. 85, no. 1, 2002, pages 161 - 71
SINGHA; DEY, FITOTERAPIA, vol. 74, 2003, pages 692 - 694
STIRLING R. G ET AL., BR MED BULL, vol. 56, no. 4, 2000, pages 1037 - 53
TAKASHIBA S. ET AL., J PERIODONTOL., vol. 74, no. 1, 2003, pages 103 - 10
TAYLOR P.C. ET AL., CURR PHARM DES., vol. 9, no. 14, 2003
TAYLOR P.C. ET AL., CURR PHARM DES., vol. 9, no. 14, 2003, pages 1095 - 106
TOWNSEND ET AL., BIOSCIENCES INFORMATION SERVICE, 2001
TSIMBERIDOU A.M. ET AL., EXPERT REV ANTICANCER THER, vol. 2, no. 3, 2002
TUTUNCU Z. ET AL., CLIN EXP RHEUMATOL., vol. 20, no. 6, 2002, pages 146 - 51
VAN DER MEER J. W. ET AL., ANN N YACAD SCI., vol. 856, 1998, pages 243 - 51
VAN REETH K. ET AL., VET IMMUNOL IMMUNOPATHOL., vol. 87, no. 3-4, 2002, pages 161 - 8
WANG C. X. ET AL., PROG NEUROBIOL, vol. 67, no. 2, 2002, pages 161 - 72
WANG C.X. ET AL., PROG NEUROBIOL., vol. 67, no. 2, 2002, pages 161 - 72
WEINBERG J. M. ET AL., CUTIS, vol. 71, no. 1, 2003, pages 41 - 5
WILKINSON N. ET AL., ARCH DIS CHILD., vol. 88, no. 3, 2003, pages 186 - 91
ZHAO ET AL., PHYTOCHEMICAL ANALYSIS, vol. 13, 2002, pages 222 - 227

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE42718E1 (en) 2004-04-28 2011-09-20 Hutchison Medipharma Enterprises Limited Crude extracts from andrographis paniculata
USRE43423E1 (en) 2004-04-28 2012-05-29 Hutchison Medipharma Enterprises Limited Crude extracts from Andrographis paniculata
JP2007176934A (en) * 2005-11-30 2007-07-12 Kose Corp Platelet-activating factor acetylhydrolase function regulator
JP2009544687A (en) * 2006-07-28 2009-12-17 インデナ エッセ ピ ア Methods for treating and preventing mucositis
US8557302B2 (en) 2007-11-02 2013-10-15 Nutrition Science Partners Limited Andrographis paniculata extract
JP2015025024A (en) * 2007-11-02 2015-02-05 ニュートリション サイエンス パートナーズ リミテッドＮｕｔｒｉｔｉｏｎ Ｓｃｉｅｎｃｅ Ｐａｒｔｎｅｒｓ Ｌｉｍｉｔｅｄ Andrographis paniculata extract and pharmaceutical composition comprising the extract and use in the manufacture of pharmaceutical composition of the extract
JP2011502995A (en) * 2007-11-02 2011-01-27 ハッチソン メディファーマ エンタープライジズ リミテッド Andrographis Paniculata Extract
EP2217254A4 (en) * 2007-11-02 2012-04-18 Hutchison Medipharma Entpr Ltd Andrographis paniculata extract
US8557308B2 (en) 2007-11-02 2013-10-15 Nutrition Science Partners Limited Andrographis paniculata extract
AU2008318487B2 (en) * 2007-11-02 2013-08-01 Nutrition Science Partners Limited Andrographis paniculata extract
WO2010110748A1 (en) * 2009-03-24 2010-09-30 National University Of Singapore Use of andrographolide compounds for treating inflammation and airway disorders
CN102702147A (en) * 2012-06-18 2012-10-03 辽宁利锋科技开发有限公司 Andrographolide analogue and application of andrographolide analogue to treatment
CN103145661A (en) * 2013-03-25 2013-06-12 成都天台山制药有限公司 New crystal form of andrographolide
CN103145661B (en) * 2013-03-25 2014-06-18 成都天台山制药有限公司 New crystal form of andrographolide
WO2017204619A1 (en) * 2016-05-23 2017-11-30 Universiti Putra Malaysia (Upm) Extract of andrographis paniculata for cognitive enhancement
US10780138B2 (en) 2016-05-23 2020-09-22 Universiti Putra Malaysia (Upm) Extract of andrographis paniculata for cognitive enhancement
WO2018081959A1 (en) * 2016-11-02 2018-05-11 Nutrition Science Partners Limited Extracts of andrographis paniculata, methods for preparation and use thereof
WO2018082568A1 (en) 2016-11-02 2018-05-11 Nutrition Science Partners Limited Extracts of andrographis paniculata, methods for preparation and use thereof
CN110049762A (en) * 2016-11-02 2019-07-23 营养科学合作伙伴有限公司 Andrographis Paniculata and its preparation method and application
EP3534895A4 (en) * 2016-11-02 2020-07-29 Nutrition Science Partners Limited Extracts ofandrographis paniculata
US11191798B2 (en) 2016-11-02 2021-12-07 Nutrition Science Partners Limited Extracts of Andrographis paniculata, methods for preparation and use thereof
WO2022058422A1 (en) * 2020-09-17 2022-03-24 Dsm Ip Assets B.V. Use of andrographis paniculata extract to protect against air pollution related diseases

Also Published As

Publication number Publication date
DK1747008T3 (en) 2015-03-30
EP1747008A4 (en) 2009-04-22
TWI373340B (en) 2012-10-01
KR20070033982A (en) 2007-03-27
JP5221128B2 (en) 2013-06-26
WO2005104722A3 (en) 2006-03-02
EP1747008B1 (en) 2015-01-14
KR20130012979A (en) 2013-02-05
PL1747008T3 (en) 2015-10-30
RU2006141834A (en) 2008-06-10
PT1747008E (en) 2015-03-31
KR20150047645A (en) 2015-05-04
HUE025117T2 (en) 2016-02-29
KR101536892B1 (en) 2015-07-14
RU2383353C2 (en) 2010-03-10
KR101534844B1 (en) 2015-07-07
KR101531116B1 (en) 2015-06-23
US20060246156A1 (en) 2006-11-02
US7341748B2 (en) 2008-03-11
EP1747008A2 (en) 2007-01-31
CA2564637C (en) 2013-09-10
CA2564637A1 (en) 2005-11-10
AU2005237550B2 (en) 2010-09-23
ES2534594T3 (en) 2015-04-24
JP2007535542A (en) 2007-12-06
USRE42718E1 (en) 2011-09-20
AU2005237550A1 (en) 2005-11-10
USRE43423E1 (en) 2012-05-29
TW200538144A (en) 2005-12-01

Similar Documents

Publication Publication Date Title
USRE42718E1 (en) Crude extracts from andrographis paniculata
AU2008318487B2 (en) Andrographis paniculata extract
Govind et al. Medicinal plants: better remedy for neoplasm
US20110117121A1 (en) Compositions for treatment and inhibition of pain
US7625945B2 (en) Andrographolide and analogues as inhibitors of TNFα and IL-1β expression
CN105636647A (en) Combination therapy for prostate cancer using botanical compositions and docetaxel
US20050124684A1 (en) 5-(hydroxymethyl) furfural and derivatives as inhibitors of TNFalpha and IL-1beta production
CN108159061B (en) Polydatin-paclitaxel composition and application thereof in preparing medicine for preventing and treating gastric malignant tumor
US20050148616A1 (en) Inhibitor of TNF-alpha and IL-1beta production
KR100889169B1 (en) Preparation method of Shiho water extract showing neurokinin-1 receptor antagonistic effect and neurokinin-1 receptor antagonistic pharmaceutical composition containing shiho water extract
KR100965305B1 (en) Composition for preventing or treating a disease mediated by overexpression of HSP 27
JP2005052155A (en) Food composition containing red bean cedar and tecoma
KR101729078B1 (en) Composition for anti-obesity containing enmides
JP3693171B2 (en) Antitumor agent containing red bean cedar and tekoma
KR101711970B1 (en) A composition comprising dehydroglyasperin C for the treatment of the decline or damage of cognitive function
KR20200029702A (en) Pharmaceutical composition including abeliophyllum distichum extract for preventing or treating liver injury
KR20190014764A (en) Anti-inflammatory compositions comprising osmundalacton and/or 3,5-Dihydroxy-γ-caprolactone

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1252/MUMNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2564637

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005237550

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007510891

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005742174

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005237550

Country of ref document: AU

Date of ref document: 20050426

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005237550

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006141834

Country of ref document: RU

Ref document number: 1020067025043

Country of ref document: KR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005742174

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067025043

Country of ref document: KR